Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Receivables (2017 - 2025)

Organogenesis Holdings has reported Change in Receivables over the past 10 years, most recently at $51.5 million for Q4 2025.

  • Quarterly results put Change in Receivables at $51.5 million for Q4 2025, up 484.71% from a year ago — trailing twelve months through Dec 2025 was $115.8 million (up 264.16% YoY), and the annual figure for FY2025 was $115.8 million, up 264.16%.
  • Change in Receivables for Q4 2025 was $51.5 million at Organogenesis Holdings, up from $50.7 million in the prior quarter.
  • Over the last five years, Change in Receivables for ORGO hit a ceiling of $51.5 million in Q4 2025 and a floor of -$7.3 million in Q4 2023.
  • Median Change in Receivables over the past 5 years was $5.2 million (2021), compared with a mean of $9.0 million.
  • Biggest five-year swings in Change in Receivables: plummeted 166.42% in 2023 and later surged 1799.8% in 2025.
  • Organogenesis Holdings' Change in Receivables stood at $8.5 million in 2021, then crashed by 132.21% to -$2.7 million in 2022, then plummeted by 166.42% to -$7.3 million in 2023, then soared by 220.6% to $8.8 million in 2024, then soared by 484.71% to $51.5 million in 2025.
  • The last three reported values for Change in Receivables were $51.5 million (Q4 2025), $50.7 million (Q3 2025), and $19.3 million (Q2 2025) per Business Quant data.